002720.KS
Kukje Pharma Co., Ltd.
KSC · Healthcare · Drug Manufacturers - Specialty & Generic · KR
KRW 3,385.00
−0.88%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 181.3B | 175.5B | 156.5B | 135.4B | 126.6B |
| Cost of Revenue | 84.4B | 82.5B | 74.0B | 68.1B | 63.3B |
| Gross Profit | 96.9B | 93.0B | 82.5B | 67.2B | 63.3B |
| Operating Expenses | |||||
| R&D Expense | 7.0B | 6.7B | 1.8B | 5.0B | 2.0B |
| SG&A Expense | 78.5B | 68.1B | 58.0B | 43.1B | 27.6B |
| General & Admin Expense | 4.7B | 6.2B | 4.4B | 6.9B | 4.8B |
| Selling & Marketing Expense | 47.7B | 61.9B | 53.6B | 36.2B | 22.7B |
| Other Expenses | 11.0B | 12.1B | 16.0B | 23.4B | 28.4B |
| Total Operating Expenses | 92.4B | 86.8B | 75.8B | 69.2B | 58.0B |
| Cost and Expenses | 176.8B | 169.3B | 149.8B | 137.4B | 121.3B |
| Operating Income (EBIT) | 4.5B | 6.2B | 6.7B | (2.0B) | 5.3B |
| Non-Operating | |||||
| Interest Income | 431.2M | 480.7M | 428.7M | 394.0M | 230.9M |
| Interest Expense | 802.3M | 908.4M | 1.2B | 1.4B | 1.0B |
| Net Interest Income | (371.1M) | (427.7M) | (777.2M) | (1.0B) | (769.6M) |
| Other Non-Op Income/Expense | 1.2B | 258.6M | (92.4M) | (4.7B) | (527.4M) |
| Non-Operating Income (excl Interest) | (923.7M) | — | (1.1B) | 3.3B | (473.0M) |
| EBT (Pre-Tax Income) | 5.7B | 6.4B | 6.6B | (6.7B) | 4.7B |
| Income Tax Expense | 687.5M | 738.5M | 1.4B | 1.7B | 1.2B |
| Bottom Line | |||||
| Net Income | 5.0B | 5.7B | 5.2B | (8.4B) | 3.6B |
| Earnings from Cont. Ops | 5.0B | 5.7B | 5.2B | (8.4B) | 3.5B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 5.0B | 5.7B | 5.2B | (8.4B) | 3.6B |
| Per Share | |||||
| Basic EPS | ₩240 | ₩280 | ₩256 | (₩415) | ₩176 |
| Diluted EPS | ₩240 | ₩280 | ₩256 | (₩415) | ₩176 |
| Revenue Per Share | ₩8,567 | ₩8,609 | ₩7,684 | ₩6,684 | ₩6,248 |
| Shares | |||||
| Basic Shares Outstanding | 21.2M | 20.4M | 20.4M | 20.3M | 20.3M |
| Diluted Shares Outstanding | 21.2M | 20.4M | 20.4M | 20.3M | 20.3M |
| Profitability Metrics | |||||
| EBITDA | 8.6B | 9.4B | 11.0B | (1.0B) | 10.2B |
| D&A | 3.4B | 3.2B | 3.2B | 4.2B | 4.5B |
| EBIT | 5.2B | 6.2B | 7.8B | (5.2B) | 5.7B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026